This is a one-year, double-blind placebo-controlled randomized clinical trial that compares
montelukast to placebo in individuals with mild cognitive impairment (MCI) and early
Alzheimer's disease (AD) dementia. The measures include cognitive function, CSF biomarkers
and neuroimaging (cerebral perfusion and markers of vascular brain damage).
Participants will be treated with montelukast (escalating doses:10, 20 to 40 mg) or matched
placebo.